Anxiety Treatment In Santa Barbara With Lucid Therapeutics

January 22, 2024
5 min read
Blog
Anxiety Treatment In Santa Barbara With Lucid Therapeutics

Understanding Anxiety

Anxiety is a complex and often debilitating mental health condition that affects millions of individuals worldwide. Experiencing occasional anxiety can be a common aspect of life. However, individuals with anxiety disorders often endure heightened, disproportionate, and persistent levels of concern and fear in routine situations. Anxiety disorders frequently manifest as recurring episodes of intense anxiety and terror, often culminating in rapid peak experiences known as panic attacks. These feelings of anxiety and panic can significantly disrupt daily activities, proving challenging to manage.

Traditional treatment methods may not always provide the relief needed for those grappling with severe anxiety. If you or a loved one is struggling with anxiety, our innovative treatment approach using Ketamine and post-session therapy might be the solution you’ve been searching for. At Lucid Therapeutics, we recognize the challenges posed by anxiety, and we’re committed to offering a unique and effective solution with Ketamine therapy.

The Role of Ketamine In Anxiety Treatment

Ketamine, traditionally known as an anesthetic, has shown remarkable potential in treating various mental health conditions, including anxiety. Recent studies and clinical trials have highlighted its ability to rapidly alleviate symptoms of anxiety, providing a new avenue for individuals seeking relief.

When it comes to understanding the potential effects of ketamine therapy, it’s crucial to examine the fascinating way it interacts with our brain. Traditional antidepressants typically target serotonin or norepinephrine pathways, but ketamine takes a distinctively different route. It hones in on the brain’s glutamate system, the most prevalent neurotransmitter in the mammalian brain which is  indispensable in the formation of synaptic plasticity – the capacity of synapses to either strengthen or weaken connections over time. This adaptability of synapses is integral to our abilities to learn and remember and change how we respond to our environment and our own thoughts.

Here’s where ketamine works its magic: it blocks specific glutamate receptors, known as NMDA receptors. This blocking action releases your mind from using the same synapse that had it stuck in a maladaptive mental pattern and allows for the  development of new synapses, thus enhancing neural connections throughout the brain and allowing change. This improved connectivity allows for the lifting of the heavy veil of depression and anxiety, providing a fresh, revitalized perspective. The unique pathway ketamine takes within the brain is indeed the foundation of its transformative power, making it a truly innovative approach in the realm of mental health treatment.

How Effective Is Ketamine Therapy For Anxiety Treatment?

In a review conducted in 2022, researchers observed that single-dose ketamine infusions demonstrated a reduction in panic, irritability, and other anxiety symptoms among individuals with Generalized Anxiety Disorder (GAD) and social anxiety disorder. The study indicated that higher doses of ketamine exhibited greater efficacy compared to lower doses, and the anxiety-relieving effects were sustained for up to 2 weeks.

A study conducted in 2017 revealed that 82% of participants diagnosed with GAD and social anxiety disorder reported a significant decrease in anxiety symptoms within just 1 hour after receiving subcutaneous (under the skin) ketamine treatments.

In another study from 2013 involving hospice residents with depression and anxiety, oral ketamine was administered for 28 days. All eight participants who completed the trial reported a reduction in anxiety symptoms.

A 2017 study focused on individuals with social anxiety who received intravenous (IV) infusions containing either saline (a placebo) or ketamine. Those who received the ketamine infusion reported significantly greater improvements in their symptoms compared to those who received the placebo.

Why Lucid Therapeutics?

At Lucid Therapeutics, we specialize in providing personalized and comprehensive Ketamine-assisted therapy for anxiety. Our team of experienced professionals is dedicated to creating a supportive and nurturing environment for our patients. We understand that each individual’s journey with anxiety is unique, and our tailored approach ensures the best possible outcomes.

Our vision is to inspire our patients with agency to release barriers, expand their awareness, and connect with their true self. Our mission is to provide safe, supportive, and insightful psychedelic therapy and integration that empowers people to break free from their limitations and make purposeful change in their lives.

We pride ourselves on:

Our Experienced and Caring Professionals: Lucid was founded by Dr. Remi Drozd, a board certified physician with 15 years experience improving the wellbeing of his patients. Our team consists of skilled professionals with a deep understanding of Ketamine-assisted therapy for anxiety treatment.

Personalized Treatment Plans: We believe in individualized care, tailoring treatment plans to meet the specific needs of each patient.

Safe and Controlled Environment: Lucid Therapeutics provides a safe and controlled environment for Ketamine administration, ensuring the highest standards of care.

Unique Approach To Integration: Within 3 days after each ketamine session, you’ll have a personalized integration coaching session. This is an opportunity to step back and reflect on your experiences and emphasize meaning that is otherwise overlooked.

We are not another infusion center. We collaboratively discover your intentions for the therapy, build a customized care plan, and pair you with an integration coach who partners with you every step of the way to ensure you make meaning of your treatment.

Want to learn more about our mission and team? Click here.

Embark on your journey towards an anxiety-free life by scheduling an appointment with Lucid Therapeutics. Take control of your mental well-being and explore the possibilities offered by Ketamine-assisted therapy.

Contact us to schedule a consultation today.

Sources:

  1. Krystal, J. H., & Neumeister, A. (2009). Ketamine as a novel antidepressant: from synapse to behavior. Clinical Pharmacology & Therapeutics, 85(6), 711–713.
  2. Murrough, J. W., et al. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. American Journal of Psychiatry, 170(10), 1134–1142.
  3. Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry, 23(4), 801–811.
  4. Feder, A., et al. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry, 71(6), 681–688.
  5. Newport, D. J., et al. (2015). Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. The American Journal of Psychiatry, 172(10), 950–966.
  6. Niciu, M. J., et al. (2014). Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annual Review of Pharmacology and Toxicology, 54, 119–139.
  7. Domany, Y., et al. (2019). Ketamine’s antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. International Journal of Neuropsychopharmacology, 22(8), 485–492.
  8. Wilkinson, S. T., et al. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. American Journal of Psychiatry, 175(2), 150–158.
  9. McGirr, A., et al. (2015). A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine, 45(4), 693–704.
  10. Murrough, J. W., et al. (2017). Targeting glutamate signalling in depression: progress and prospects. Nature Reviews Drug Discovery, 16(7), 472–486.